Month: April 2020

Basel, Switzerland, April 29, 2020Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that Ms. Savitha Ram Moorthi will be appointed Head of Global Quality Management and a member of the Extended Management Committee of Basilea as of June 1, 2020. Ms. Ram Moorthi joined Basilea from Novo Nordisk Health Care, Zurich, Switzerland, on February 1, 2020, as Head of Quality Compliance Systems & Safety. She holds a Master’s Degree in Clinical Pharmacology from the University of Aberdeen, United Kingdom, and a Master’s in Pharmacy from Nagpur University, India. At Novo Nordisk, Ms. Ram Moorthi served as Director Clinical Quality and Pharmacovigilance responsible for the oversight of Quality Management Reviews, clinical quality and pharmacovigilance for International Operations. Prior to this, she worked as Director Clinical Operations...

Basel, 29. April 2020Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass Frau Savitha Ram Moorthi zum 1. Juni 2020 zum Head of Global Quality Management und Mitglied der erweiterten Geschäftsleitung der Basilea ernannt wird. Frau Ram Moorthi kam als Head of Quality Compliance Systems & Safety am 1. Februar 2020 von Novo Nordisk Health Care, Zürich, zu Basilea. Sie verfügt über einen Master-Abschluss in klinischer Pharmakologie der Universität von Aberdeen, Grossbritannien, und einen Master-Abschluss in Pharmazie der Universität von Nagpur, Indien. Bei Novo Nordisk war Frau Ram Moorthi als Director Clinical Quality and Pharmacovigilance für die Leitung von Qualitätsmanagement-Reviews, klinische Qualität und Arzneimittelsicherheit (Pharmakovigilanz) für das internationale Geschäft verantwortlich. Davor war sie Director Clinical...

Cosentyx® is the first fully-human IL-17A inhibitor indicated for patients in Europe with non-radiographic axial spondyloarthritis (nr-axSpA), which forms part of the axial spondyloarthritis (axSpA) disease spectrum There are approximately 1.7 million patients with nr-axSpA in the top five EU countries and US1 Cosentyx is also approved for the treatment of moderate-to-severe plaque psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS)2-4 This approval underlines Cosentyx leadership in rheumatology and immuno-dermatology, with plans to expand to 10 indications over the next 10 years Basel, April 29, 2020 — Novartis, a leader in rheumatology and immuno-dermatology,  today announced the European Commission (EC) has approved Cosentyx® (secukinumab) for the treatment of adult patients with active non-radiographic axial...

PRESS RELEASEFIRST-QUARTER 2020 BUSINESS REVIEWParis — April 29, 2020Key financials(1)Operating performanceRevenuesKlépierre’s total revenues for the three-month period ended March 31, 2020 amounted to €316.8 million, a 4.2% decrease compared to the same period last year, mainly attributable to the impact of disposals carried out in 2019.Gross rental income generated by shopping centers amounted to €291.9 million over the first quarter of 2020 on a total share basis, compared to €304.9 million for the same period last year. The €13.0-million (4.3%) decrease mainly reflects the disposal of assets in Hungary, Portugal and the Netherlands in 2019 as well as a negative foreign exchange effect from Scandinavian currencies.As of March 31, 2020, like-for-like basis(2) shopping centers net rental income was broadly stable compared to the same...

COMMUNIQUÉ DE PRESSEACTIVITÉ DU PREMIER TRIMESTRE 2020Paris, le 29 avril 2020Données financières clés(1)Performance opérationnelleChiffre d’affairesAu cours du premier trimestre 2020, le chiffre d’affaires total de Klépierre s’est établi à 316,8 M€, en baisse de 4,2 % par rapport à la même période l’an dernier, principalement en raison des cessions réalisées en 2019.Les revenus locatifs bruts des centres commerciaux ont atteint 291,9 M€ au premier trimestre (en part totale) contre 304,9 M€ à la même période l’an dernier. La baisse de 13,0 M€, soit 4,3 %, est principalement liée aux cessions d’actifs réalisées en 2019 en Hongrie, au Portugal et aux Pays-Bas ainsi qu’à un effet de change défavorable des monnaies scandinaves.Au 31 mars 2020, à périmètre constant(2), les revenus locatifs nets des centres commerciaux sont restés stables (+...

HUHTAMÄKI OYJ INTERIM REPORT 29.4.2020 AT 8:00Huhtamäki Oyj’s Interim Report January 1–March 31, 2020: Solid net sales growth and profitability in an increasingly uncertain environmentQ1 2020 in briefNet sales increased 5% to EUR 845 million (EUR 802 million)Adjusted EBIT was EUR 74 million (EUR 68 million); reported EBIT was EUR 83 million (EUR 68 million)Adjusted EPS was EUR 0.46 (EUR 0.44); reported EPS was EUR 0.53 (EUR 0.44)Comparable net sales growth was 3% at Group level and -3% in emerging marketsCurrency movements had a positive impact of EUR 10 million on the Group’s net sales and EUR 1 million on EBITKey figures1Excluding IAC of EUR 13.1 million in Q1 2020 (EUR -0.1 million) and EUR -7.6 million in 2019.2Excluding IAC of EUR 8.9 million in Q1 2020 (EUR -0.1 million) and EUR -7.6 million in 2019.3Excluding IAC of EUR 6.9 million...

HUHTAMÄKI OYJ OSAVUOSIKATSAUS 29.4.2020 KLO 8.00Huhtamäki Oyj:n osavuosikatsaus 1.1.–31.3.2020: Vakaa liikevaihdon kasvu ja kannattavuus yhä epävarmemmaksi muuttuneessa toimintaympäristössäQ1 2020 lyhyesti

(Oslo, Norway, 29 April 2020) StrongPoint ASA (StrongPoint, OSE: STRONG) reported revenues of NOK 279.8 million in the first quarter of 2020, down from NOK 288.2 million in the same quarter in 2019. The company’s EBITDA in the period came in at NOK 16.5 million (27.7), impacted amongst others by a negative currency effect of NOK 4 million. StrongPoint experiences short-term effects from the COVID-19-situation but reiterates the 2025 ambition of NOK 2.5 billion in revenues and EBITDA margins of 13-15%.           “In the last few weeks, our main focus has been upholding the highest level of safety for our employees, customers and business partners as part of the joint pan-national efforts to protect vulnerable groups. I would like to express my gratitude to the entire StrongPoint team and to our partners for their dedication and hard work...

Borregaard’s operating revenues increased to NOK 1,372 million (NOK 1,250 million)¹ in the 1st quarter of 2020. EBITDA² was NOK 242 million (NOK 255 million). BioSolutions (ligninbased biopolymers and biovanillin) and BioMaterials (speciality cellulose and cellulose fibrils) had results in line with the 1st quarter of 2019, whereas Fine Chemicals (pharma intermediates and bioethanol) had a decline. The Group has not been materially impacted by the coronavirus situation during the 1st quarter of 2020.BioSolutions had a positive development within Specialities, while both BioMaterials and Fine Chemicals had an unfavourable product mix in the quarter. Operating costs were higher due to increased transatlantic shipments, maintenance and an IT transition project. Wood costs were gradually reduced during the quarter, but less than expected.The...

Polarcus Limited (“Polarcus” or the “Company”) (OSE: PLCS) announces that an award has been received for an XArray™ marine seismic acquisition project in Asia Pacific, that is expected to commence in June 2020 with a duration of approximately 1 month. ContactsHans-Peter Burlid, CFO+971 50 559 8175hp.burlid@polarcus.comLars Oestergaard, COO+971 54 791 0564lars.oestergaard@polarcus.com About PolarcusThis information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.